A Novel Triple-Action Inhibitor Targeting B-Cell Receptor Signaling and BRD4 Demonstrates Preclinical Activity in Chronic Lymphocytic Leukemia

B-cell chronic lymphocytic leukemia (CLL) results from intrinsic genetic defects and complex microenvironment stimuli that fuel CLL cell growth through an array of survival signaling pathways. Novel small-molecule agents targeting the B-cell receptor pathway and anti-apoptotic proteins alone or in c...

Descripción completa

Detalles Bibliográficos
Autores principales: Smith, Audrey L., Eiken, Alexandria P., Skupa, Sydney A., Moore, Dalia Y., Umeta, Lelisse T., Smith, Lynette M., Lyden, Elizabeth R., D’Angelo, Christopher R., Kallam, Avyakta, Vose, Julie M., Kutateladze, Tatiana G., El-Gamal, Dalia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9224275/
https://www.ncbi.nlm.nih.gov/pubmed/35743155
http://dx.doi.org/10.3390/ijms23126712

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9224275/
https://www.ncbi.nlm.nih.gov/pubmed/35743155
http://dx.doi.org/10.3390/ijms23126712

Ejemplares similares